Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Resistant Pseudomonas Aeruginosa Infections Drugs by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Resistant Pseudomonas Aeruginosa Infections Drugs by Country/Region, 2017, 2022 & 2028

2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type

2.2.1 Semi-Synthetic Penicillin

2.2.2 Cephalosporin

2.2.3 Lactam Drugs

2.2.4 Others

2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type

2.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2017-2022)

2.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2017-2022)

2.3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Type (2017-2022)

2.4 Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Home Care

2.5 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application

2.5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Market Share by Application (2017-2022)

2.5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Application (2017-2022)

2.5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Application (2017-2022)

3 Global Resistant Pseudomonas Aeruginosa Infections Drugs by Company

3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Breakdown Data by Company

3.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Sales by Company (2020-2022)

3.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Company (2020-2022)

3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Revenue by Company (2020-2022)

3.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Company (2020-2022)

3.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Company (2020-2022)

3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Company

3.4 Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Location Distribution

3.4.2 Players Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Resistant Pseudomonas Aeruginosa Infections Drugs by Geographic Region

4.1 World Historic Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Geographic Region (2017-2022)

4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Revenue by Geographic Region

4.2 World Historic Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country/Region (2017-2022)

4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Sales by Country/Region (2017-2022)

4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Revenue by Country/Region

4.3 Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth

4.4 APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth

4.5 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth

4.6 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth

5 Americas

5.1 Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country

5.1.1 Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2017-2022)

5.1.2 Americas Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2017-2022)

5.2 Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type

5.3 Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region

6.1.1 APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2017-2022)

6.1.2 APAC Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2017-2022)

6.2 APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type

6.3 APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs by Country

7.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2017-2022)

7.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2017-2022)

7.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type

7.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs by Country

8.1.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2017-2022)

8.1.2 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2017-2022)

8.2 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type

8.3 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

10.3 Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

10.4 Industry Chain Structure of Resistant Pseudomonas Aeruginosa Infections Drugs

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors

11.3 Resistant Pseudomonas Aeruginosa Infections Drugs Customer

12 World Forecast Review for Resistant Pseudomonas Aeruginosa Infections Drugs by Geographic Region

12.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Region

12.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Forecast by Region (2023-2028)

12.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Resistant Pseudomonas Aeruginosa Infections Drugs Forecast by Type

12.7 Global Resistant Pseudomonas Aeruginosa Infections Drugs Forecast by Application

13 Key Players Analysis

13.1 ContraFect Corp

13.1.1 ContraFect Corp Company Information

13.1.2 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 ContraFect Corp Main Business Overview

13.1.5 ContraFect Corp Latest Developments

13.2 Inhibrx LP

13.2.1 Inhibrx LP Company Information

13.2.2 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Inhibrx LP Main Business Overview

13.2.5 Inhibrx LP Latest Developments

13.3 Achaogen Inc

13.3.1 Achaogen Inc Company Information

13.3.2 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Achaogen Inc Main Business Overview

13.3.5 Achaogen Inc Latest Developments

13.4 LegoChem Biosciences Inc

13.4.1 LegoChem Biosciences Inc Company Information

13.4.2 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 LegoChem Biosciences Inc Main Business Overview

13.4.5 LegoChem Biosciences Inc Latest Developments

13.5 Melinta Therapeutics Inc

13.5.1 Melinta Therapeutics Inc Company Information

13.5.2 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Melinta Therapeutics Inc Main Business Overview

13.5.5 Melinta Therapeutics Inc Latest Developments

13.6 Novartis AG

13.6.1 Novartis AG Company Information

13.6.2 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Novartis AG Main Business Overview

13.6.5 Novartis AG Latest Developments

13.7 AmpliPhi Biosciences Corp

13.7.1 AmpliPhi Biosciences Corp Company Information

13.7.2 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 AmpliPhi Biosciences Corp Main Business Overview

13.7.5 AmpliPhi Biosciences Corp Latest Developments

13.8 Biolytics Pharma

13.8.1 Biolytics Pharma Company Information

13.8.2 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Biolytics Pharma Main Business Overview

13.8.5 Biolytics Pharma Latest Developments

13.9 Shionogi & Co Ltd

13.9.1 Shionogi & Co Ltd Company Information

13.9.2 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

13.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Shionogi & Co Ltd Main Business Overview

13.9.5 Shionogi & Co Ltd Latest Developments

14 Research Findings and Conclusion

Table 1. Resistant Pseudomonas Aeruginosa Infections Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Resistant Pseudomonas Aeruginosa Infections Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Semi-Synthetic Penicillin

Table 4. Major Players of Cephalosporin

Table 5. Major Players of Lactam Drugs

Table 6. Major Players of Others

Table 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2017-2022) & (K Pcs)

Table 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2017-2022)

Table 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2017-2022) & ($ million)

Table 10. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2017-2022)

Table 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Type (2017-2022) & (USD/Pcs)

Table 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2017-2022) & (K Pcs)

Table 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2017-2022)

Table 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2017-2022)

Table 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2017-2022)

Table 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Application (2017-2022) & (USD/Pcs)

Table 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Company (2020-2022) & (K Pcs)

Table 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Company (2020-2022)

Table 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Company (2020-2022) ($ Millions)

Table 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Company (2020-2022)

Table 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Company (2020-2022) & (USD/Pcs)

Table 22. Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Producing Area Distribution and Sales Area

Table 23. Players Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered

Table 24. Resistant Pseudomonas Aeruginosa Infections Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Geographic Region (2017-2022) & (K Pcs)

Table 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Geographic Region (2017-2022)

Table 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Geographic Region (2017-2022) & ($ millions)

Table 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country/Region (2017-2022) & (K Pcs)

Table 32. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country/Region (2017-2022)

Table 33. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country/Region (2017-2022) & ($ millions)

Table 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2017-2022) & (K Pcs)

Table 36. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2017-2022)

Table 37. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 38. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2017-2022)

Table 39. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2017-2022) & (K Pcs)

Table 40. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2017-2022)

Table 41. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2017-2022) & (K Pcs)

Table 42. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2017-2022)

Table 43. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2017-2022) & (K Pcs)

Table 44. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2017-2022)

Table 45. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2017-2022) & ($ Millions)

Table 46. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2017-2022)

Table 47. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2017-2022) & (K Pcs)

Table 48. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2017-2022)

Table 49. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2017-2022) & (K Pcs)

Table 50. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2017-2022)

Table 51. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2017-2022) & (K Pcs)

Table 52. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2017-2022)

Table 53. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 54. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2017-2022)

Table 55. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2017-2022) & (K Pcs)

Table 56. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2017-2022)

Table 57. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2017-2022) & (K Pcs)

Table 58. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2017-2022)

Table 59. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2017-2022) & (K Pcs)

Table 60. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2017-2022)

Table 61. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 62. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2017-2022)

Table 63. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2017-2022) & (K Pcs)

Table 64. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of Resistant Pseudomonas Aeruginosa Infections Drugs

Table 68. Key Market Challenges & Risks of Resistant Pseudomonas Aeruginosa Infections Drugs

Table 69. Key Industry Trends of Resistant Pseudomonas Aeruginosa Infections Drugs

Table 70. Resistant Pseudomonas Aeruginosa Infections Drugs Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List

Table 73. Resistant Pseudomonas Aeruginosa Infections Drugs Customer List

Table 74. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Region (2023-2028) & (K Pcs)

Table 75. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Forecast by Region

Table 76. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 77. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 79. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 80. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Region (2023-2028) & (K Pcs)

Table 81. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 82. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 83. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 84. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2023-2028) & (K Pcs)

Table 87. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Type (2023-2028)

Table 88. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 89. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2023-2028) & (K Pcs)

Table 91. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Application (2023-2028)

Table 92. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 93. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Application (2023-2028)

Table 94. ContraFect Corp Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 95. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 96. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 97. ContraFect Corp Main Business

Table 98. ContraFect Corp Latest Developments

Table 99. Inhibrx LP Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 100. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 101. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 102. Inhibrx LP Main Business

Table 103. Inhibrx LP Latest Developments

Table 104. Achaogen Inc Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 105. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 106. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 107. Achaogen Inc Main Business

Table 108. Achaogen Inc Latest Developments

Table 109. LegoChem Biosciences Inc Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 110. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 111. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 112. LegoChem Biosciences Inc Main Business

Table 113. LegoChem Biosciences Inc Latest Developments

Table 114. Melinta Therapeutics Inc Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 115. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 116. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 117. Melinta Therapeutics Inc Main Business

Table 118. Melinta Therapeutics Inc Latest Developments

Table 119. Novartis AG Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 120. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 121. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 122. Novartis AG Main Business

Table 123. Novartis AG Latest Developments

Table 124. AmpliPhi Biosciences Corp Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 125. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 126. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 127. AmpliPhi Biosciences Corp Main Business

Table 128. AmpliPhi Biosciences Corp Latest Developments

Table 129. Biolytics Pharma Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 130. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 131. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 132. Biolytics Pharma Main Business

Table 133. Biolytics Pharma Latest Developments

Table 134. Shionogi & Co Ltd Basic Information, Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 135. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Offered

Table 136. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 137. Shionogi & Co Ltd Main Business

Table 138. Shionogi & Co Ltd Latest Developments

List of Figures

Figure 1. Picture of Resistant Pseudomonas Aeruginosa Infections Drugs

Figure 2. Resistant Pseudomonas Aeruginosa Infections Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Semi-Synthetic Penicillin

Figure 10. Product Picture of Cephalosporin

Figure 11. Product Picture of Lactam Drugs

Figure 12. Product Picture of Others

Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2021

Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2017-2022)

Figure 15. Resistant Pseudomonas Aeruginosa Infections Drugs Consumed in Hospital

Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market: Hospital (2017-2022) & (K Pcs)

Figure 17. Resistant Pseudomonas Aeruginosa Infections Drugs Consumed in Clinic

Figure 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market: Clinic (2017-2022) & (K Pcs)

Figure 19. Resistant Pseudomonas Aeruginosa Infections Drugs Consumed in Home Care

Figure 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market: Home Care (2017-2022) & (K Pcs)

Figure 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2017-2022)

Figure 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application in 2021

Figure 23. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market by Company in 2021 ($ Million)

Figure 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Company in 2021

Figure 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Geographic Region (2017-2022)

Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Geographic Region in 2021

Figure 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2017-2022)

Figure 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country/Region in 2021

Figure 29. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2017-2022 (K Pcs)

Figure 30. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2017-2022 ($ Millions)

Figure 31. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2017-2022 (K Pcs)

Figure 32. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2017-2022 ($ Millions)

Figure 33. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2017-2022 (K Pcs)

Figure 34. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2017-2022 ($ Millions)

Figure 35. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2017-2022 (K Pcs)

Figure 36. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2017-2022 ($ Millions)

Figure 37. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2021

Figure 38. Americas Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2021

Figure 39. United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 40. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 41. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 42. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 43. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region in 2021

Figure 44. APAC Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Regions in 2021

Figure 45. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 46. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 47. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 48. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 49. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 50. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 51. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2021

Figure 52. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2021

Figure 53. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 54. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 55. UK Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 56. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 57. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 58. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2021

Figure 59. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2021

Figure 60. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 61. South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 62. Israel Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 63. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 64. GCC Country Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 65. Manufacturing Cost Structure Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs in 2021

Figure 66. Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

Figure 67. Industry Chain Structure of Resistant Pseudomonas Aeruginosa Infections Drugs

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles